PL2900694T3 - Dwuswoiste przeciwciała igg jako aktywatory komórek t - Google Patents
Dwuswoiste przeciwciała igg jako aktywatory komórek tInfo
- Publication number
- PL2900694T3 PL2900694T3 PL13777349T PL13777349T PL2900694T3 PL 2900694 T3 PL2900694 T3 PL 2900694T3 PL 13777349 T PL13777349 T PL 13777349T PL 13777349 T PL13777349 T PL 13777349T PL 2900694 T3 PL2900694 T3 PL 2900694T3
- Authority
- PL
- Poland
- Prior art keywords
- igg antibodies
- bispecific igg
- cell engagers
- engagers
- cell
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3061—Blood cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/53—Hinge
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261706543P | 2012-09-27 | 2012-09-27 | |
US201361834915P | 2013-06-14 | 2013-06-14 | |
PCT/NL2013/050693 WO2014051433A1 (en) | 2012-09-27 | 2013-09-27 | BISPECIFIC IgG ANTIBODIES AS T CELL ENGAGERS |
EP13777349.5A EP2900694B1 (en) | 2012-09-27 | 2013-09-27 | Bispecific igg antibodies as t cell engagers |
Publications (1)
Publication Number | Publication Date |
---|---|
PL2900694T3 true PL2900694T3 (pl) | 2018-12-31 |
Family
ID=49382559
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PL13777349T PL2900694T3 (pl) | 2012-09-27 | 2013-09-27 | Dwuswoiste przeciwciała igg jako aktywatory komórek t |
Country Status (27)
Country | Link |
---|---|
US (2) | US10358492B2 (pl) |
EP (2) | EP2900694B1 (pl) |
JP (2) | JP6471095B2 (pl) |
KR (1) | KR102390177B1 (pl) |
CN (2) | CN105051066B (pl) |
AU (2) | AU2013324527B9 (pl) |
BR (1) | BR112015006824A2 (pl) |
CA (1) | CA2889681C (pl) |
CY (1) | CY1120976T1 (pl) |
DK (1) | DK2900694T3 (pl) |
EA (1) | EA201590640A1 (pl) |
ES (1) | ES2692951T3 (pl) |
HK (1) | HK1211966A1 (pl) |
HR (1) | HRP20181717T1 (pl) |
HU (1) | HUE042040T2 (pl) |
IL (1) | IL237945B (pl) |
LT (1) | LT2900694T (pl) |
MX (1) | MX2015003885A (pl) |
NZ (1) | NZ630563A (pl) |
PL (1) | PL2900694T3 (pl) |
PT (1) | PT2900694T (pl) |
RS (1) | RS57910B1 (pl) |
SG (2) | SG10201705787VA (pl) |
SI (1) | SI2900694T1 (pl) |
TR (1) | TR201815768T4 (pl) |
WO (1) | WO2014051433A1 (pl) |
ZA (1) | ZA201502835B (pl) |
Families Citing this family (72)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2368733T3 (es) | 2002-07-18 | 2011-11-21 | Merus B.V. | Producción recombinante de mezclas de anticuerpos. |
USRE47770E1 (en) | 2002-07-18 | 2019-12-17 | Merus N.V. | Recombinant production of mixtures of antibodies |
ES2592271T3 (es) | 2005-03-31 | 2016-11-29 | Chugai Seiyaku Kabushiki Kaisha | Métodos de producción de polipéptidos mediante la regulación de la asociación de los polipéptidos |
EP4342995A3 (en) | 2006-03-31 | 2024-05-15 | Chugai Seiyaku Kabushiki Kaisha | Methods for controlling blood pharmacokinetics of antibodies |
PL2064325T3 (pl) | 2006-09-01 | 2012-05-31 | Therapeutic Human Polyclonals Inc | Zwiększona ekspresja ludzkiej lub humanizowanej immunoglobuliny u zwierząt transgenicznych innych niż człowiek |
WO2009041643A1 (ja) | 2007-09-26 | 2009-04-02 | Chugai Seiyaku Kabushiki Kaisha | Cdrのアミノ酸置換により抗体の等電点を改変する方法 |
PT2647707T (pt) | 2010-11-30 | 2018-11-15 | Chugai Pharmaceutical Co Ltd | Agente terapêutico indutor de toxicidade |
KR102382304B1 (ko) | 2012-04-20 | 2022-04-04 | 메뤼스 엔.페. | Ig-유사 분자의 제조방법 및 제조수단 |
CN105051066B (zh) * | 2012-09-27 | 2019-08-06 | 美勒斯公司 | 作为T细胞衔接器的双特异性IgG抗体 |
TWI635098B (zh) | 2013-02-01 | 2018-09-11 | 再生元醫藥公司 | 含嵌合恆定區之抗體 |
CN110420333A (zh) | 2013-03-14 | 2019-11-08 | 斯克利普斯研究所 | 靶向剂抗体偶联物及其用途 |
JP2016534051A (ja) * | 2013-07-04 | 2016-11-04 | フラウンホーファ−ゲゼルシャフト ツァー フォルデルング デア アンゲバンデン フォルシュンク エー. ファオ.Fraunhofer−Gesellschaft Zur Forderung Der Angewandten Forschung E. V. | 急性骨髄性白血病細胞を標的化および処置するための新規融合タンパク質 |
AU2014325063B2 (en) | 2013-09-27 | 2019-10-31 | Chugai Seiyaku Kabushiki Kaisha | Method for producing polypeptide heteromultimer |
SI3110849T1 (sl) | 2014-02-28 | 2021-01-29 | Merus N.V. | Protitelo, ki veže ERBB-2 in ERBB-3 |
AU2015223566B2 (en) | 2014-02-28 | 2020-10-08 | Merus N.V. | Antibodies that bind EGFR and ErbB3 |
TWI754319B (zh) | 2014-03-19 | 2022-02-01 | 美商再生元醫藥公司 | 用於腫瘤治療之方法及抗體組成物 |
RU2741120C2 (ru) | 2014-07-21 | 2021-01-22 | Новартис Аг | Лечение рака с использованием химерного антигенного рецептора cll-1 |
CA2958479A1 (en) | 2014-09-12 | 2016-03-17 | Genentech, Inc. | Anti-cll-1 antibodies and immunoconjugates |
MA40764A (fr) * | 2014-09-26 | 2017-08-01 | Chugai Pharmaceutical Co Ltd | Agent thérapeutique induisant une cytotoxicité |
KR102614189B1 (ko) | 2014-11-17 | 2023-12-18 | 리제너론 파아마슈티컬스, 인크. | Cd3xcd20 이특이적 항체를 이용한 종양의 치료 방법 |
RU2747011C2 (ru) * | 2014-11-20 | 2021-04-23 | Ф.Хоффманн-Ля Рош Аг | Общие легкие цепи и способы их применения |
CA2966566C (en) | 2014-11-20 | 2024-03-19 | F. Hoffmann-La Roche Ag | Combination therapy of t cell activating bispecific antigen binding molecules cd3 and folate receptor 1 (folr1) and pd-1 axis binding antagonists |
ES2882157T3 (es) * | 2015-02-13 | 2021-12-01 | Sorrento Therapeutics Inc | Productos terapéuticos de anticuerpos que se unen a CTLA4 |
CA2978594A1 (en) * | 2015-03-04 | 2016-09-09 | Sorrento Therapeutics, Inc. | Antibody therapeutics that bind cd47 |
EP3277725B1 (en) | 2015-03-30 | 2020-11-25 | Regeneron Pharmaceuticals, Inc. | Heavy chain constant regions with reduced binding to fc gamma receptors |
WO2016159213A1 (ja) | 2015-04-01 | 2016-10-06 | 中外製薬株式会社 | ポリペプチド異種多量体の製造方法 |
US10501545B2 (en) | 2015-06-16 | 2019-12-10 | Genentech, Inc. | Anti-CLL-1 antibodies and methods of use |
LT3115376T (lt) | 2015-07-10 | 2018-11-12 | Merus N.V. | Antikūnai, kurie jungiasi su žmogaus cd3 |
LT3353212T (lt) * | 2015-09-23 | 2021-12-27 | Regeneron Pharmaceuticals, Inc. | Optimizuoti anti-cd3 bispecifiniai antikūnai ir jų naudojimas |
SI3365373T1 (sl) | 2015-10-23 | 2021-08-31 | Merus N.V. | Vezne molekule, ki zaviranjo rast raka |
CN113862300A (zh) * | 2015-10-29 | 2021-12-31 | 豪夫迈·罗氏有限公司 | 具有共同轻链的转基因兔 |
MA55746A (fr) | 2016-01-21 | 2022-03-02 | Novartis Ag | Molécules multispécifiques ciblant cll-1 |
SG11201807936VA (en) | 2016-03-14 | 2018-10-30 | Chugai Pharmaceutical Co Ltd | Cell injury inducing therapeutic drug for use in cancer therapy |
WO2017210443A1 (en) * | 2016-06-01 | 2017-12-07 | Xencor, Inc. | Bispecific antibodies that bind cd123 and cd3 |
WO2018057915A1 (en) | 2016-09-23 | 2018-03-29 | The Regents Of The University Of Michigan | Engineered lymphocytes |
KR20190118172A (ko) * | 2017-02-08 | 2019-10-17 | 드래곤플라이 쎄라퓨틱스, 인크. | 천연 킬러 세포의 활성화를 위한 다중-특이적 결합 단백질 및 암 치료에서의 그의 치료적 용도 |
KR20190120782A (ko) * | 2017-02-20 | 2019-10-24 | 드래곤플라이 쎄라퓨틱스, 인크. | Her2, nkg2d 및 cd16에 결합하는 단백질 |
CN110891976A (zh) * | 2017-02-20 | 2020-03-17 | 蜻蜓疗法股份有限公司 | 结合gd2、nkg2d和cd16的蛋白质 |
WO2018182422A1 (en) | 2017-03-31 | 2018-10-04 | Merus N.V. | Erbb-2 and erbb3 binding bispecific antibodies for use in the treatment f cells that have an nrg1 fusion gene |
US20200157226A1 (en) * | 2017-05-23 | 2020-05-21 | Dragonfly Therapeutics, Inc. | Proteins binding nkg2d, cd16 and a tumor-associated antigen |
WO2018217947A1 (en) * | 2017-05-23 | 2018-11-29 | Dragonfly Therapeutics, Inc. | A protein binding nkg2d, cd16 and a tumor-associated antigen |
EA202090005A1 (ru) * | 2017-07-06 | 2020-06-18 | Мерус Н.В. | Антитела, модулирующие биологическую активность, проявляемую клеткой |
CN111094347A (zh) * | 2017-07-06 | 2020-05-01 | 美勒斯公司 | 调节由细胞表达的生物活性的结合分子 |
CA3068932A1 (en) * | 2017-07-06 | 2019-01-10 | Merus N.V. | Bispecific anti pd1-anti tim3 antibodies |
SG11202001050PA (en) | 2017-08-09 | 2020-03-30 | Merus Nv | Antibodies that bind egfr and cmet |
CN111432832A (zh) * | 2017-09-14 | 2020-07-17 | 蜻蜓疗法股份有限公司 | 结合nkg2d、cd16和c-型凝集素样分子-1(cll-1)的蛋白质 |
EP3693013A4 (en) | 2017-10-06 | 2021-06-30 | Ono Pharmaceutical Co., Ltd. | BISPECIFIC ANTIBODY |
US11161911B2 (en) | 2017-10-23 | 2021-11-02 | Go Therapeutics, Inc. | Anti-glyco-MUC1 antibodies and their uses |
CN111432838A (zh) | 2017-12-01 | 2020-07-17 | 美勒斯公司 | 使用双特异性抗体和il-15进行联合治疗 |
MX2020008336A (es) | 2018-02-08 | 2020-09-21 | Dragonfly Therapeutics Inc | Dominios variables de anticuerpos que se dirigen al receptor nkg2d. |
TWI804572B (zh) * | 2018-02-09 | 2023-06-11 | 日商小野藥品工業股份有限公司 | 雙特異性抗體 |
WO2019190327A2 (en) * | 2018-03-30 | 2019-10-03 | Merus N.V. | Multivalent antibody |
CA3100724A1 (en) | 2018-06-13 | 2019-12-19 | Novartis Ag | B-cell maturation antigen protein (bcma) chimeric antigen receptors and uses thereof |
US20220106374A1 (en) * | 2018-06-22 | 2022-04-07 | Cugene Inc | Novel interleukin-15 (il-15) fusion proteins and uses thereof |
MX2021002190A (es) | 2018-08-31 | 2021-05-14 | Regeneron Pharma | Estrategia de dosificacion que mitiga el sindrome de liberacion de citoquinas para los anticuerpos biespecificos cd3/cd20. |
CA3114707A1 (en) * | 2018-10-19 | 2020-04-23 | Regents Of The University Of Minnesota | Nk engager molecules and methods of use thereof |
US20210340274A1 (en) * | 2018-10-25 | 2021-11-04 | The Medical College Of Wisconsin, Inc. | Targeting CLPTMIL for Treatment and Prevention of Cancer |
CN114344461A (zh) * | 2018-12-20 | 2022-04-15 | 美勒斯公司 | 用于治疗疾病的CLEC12AxCD3双特异性抗体和方法 |
CN113439089A (zh) | 2018-12-31 | 2021-09-24 | 美勒斯公司 | 截短的多价多元体 |
TW202039578A (zh) | 2019-03-29 | 2020-11-01 | 荷蘭商美勒斯公司 | Cd3結合分子 |
TW202102544A (zh) | 2019-04-04 | 2021-01-16 | 日商小野藥品工業股份有限公司 | 雙特異性抗體 |
JP2022531306A (ja) * | 2019-05-04 | 2022-07-06 | インヒブルクス インコーポレイテッド | CLEC12a結合性ポリペプチド及びその使用 |
TWI809286B (zh) | 2019-07-05 | 2023-07-21 | 日商小野藥品工業股份有限公司 | 以pd-1/cd3雙特異性蛋白質所進行之血液性癌症治療 |
JP6856183B1 (ja) | 2019-07-30 | 2021-04-07 | 小野薬品工業株式会社 | 二重特異性抗体 |
JPWO2021025140A1 (pl) | 2019-08-08 | 2021-02-11 | ||
AU2020368354A1 (en) * | 2019-10-17 | 2022-05-12 | Regents Of The University Of Minnesota | CLEC12A antibody fragment sequences and methods |
IL294181A (en) | 2019-12-24 | 2022-08-01 | Merus Nv | tgf-beta-rii binding proteins |
WO2022031935A1 (en) | 2020-08-05 | 2022-02-10 | Dragonfly Therapeutics, Inc. | Antibodies targeting egfr and use thereof |
AR125451A1 (es) * | 2021-04-26 | 2023-07-19 | Millennium Pharm Inc | Anticuerpos anti-clec12a y usos de los mismos |
EP4373856A1 (en) * | 2021-07-20 | 2024-05-29 | ABL Bio Inc. | Anti-cll-1 antibodies and uses thereof |
US20230220106A1 (en) | 2021-12-08 | 2023-07-13 | Dragonfly Therapeutics, Inc. | Antibodies targeting 5t4 and uses thereof |
GB202214132D0 (en) * | 2022-09-27 | 2022-11-09 | Coding Bio Ltd | CLL1 binding molecules |
Family Cites Families (56)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US4801687A (en) | 1986-10-27 | 1989-01-31 | Bioprobe International, Inc. | Monoclonal antibody purification process using protein A |
FI884924A (fi) | 1987-10-28 | 1989-04-29 | Oncogen | Humanimmuglobulin som producerats med hybrid-dna-teknik. |
US5151504A (en) | 1989-11-17 | 1992-09-29 | E. R. Squibb & Sons, Inc. | Method for purification of monoclonal antibodies |
GB9022543D0 (en) | 1990-10-17 | 1990-11-28 | Wellcome Found | Antibody production |
TW373023B (en) | 1991-07-15 | 1999-11-01 | Wellcome Found | Production of antibodies |
US5457035A (en) | 1993-07-23 | 1995-10-10 | Immunex Corporation | Cytokine which is a ligand for OX40 |
US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
US20020062010A1 (en) | 1997-05-02 | 2002-05-23 | Genentech, Inc. | Method for making multispecific antibodies having heteromultimeric and common components |
CA2288600C (en) | 1997-05-02 | 2010-06-01 | Genentech, Inc. | A method for making multispecific antibodies having heteromultimeric and common components |
ATE536417T1 (de) | 1999-04-15 | 2011-12-15 | Crucell Holland Bv | Herstellung von rekombinanten proteinen in einer menschlichen zelle mit mindestens einem e1 adenovirus protein |
PT1600510E (pt) | 2001-07-04 | 2007-06-25 | Chromagenics Bv | Sequências de adn com actividade anti-repressora. |
EP1510943A4 (en) | 2002-05-31 | 2007-05-09 | Celestar Lexico Sciences Inc | INTERACTION PREDICTION DEVICE |
ES2368733T3 (es) | 2002-07-18 | 2011-11-21 | Merus B.V. | Producción recombinante de mezclas de anticuerpos. |
AU2003298799A1 (en) * | 2002-12-02 | 2004-06-23 | Abgenix, Inc. | Antibodies directed to phospholipase a2 and uses thereof |
PT1583830E (pt) | 2003-01-07 | 2006-11-30 | Symphogen As | Método para produzir proteínas policlonais recombinantes |
US20100069614A1 (en) | 2008-06-27 | 2010-03-18 | Merus B.V. | Antibody producing non-human mammals |
AU2004251890B2 (en) * | 2003-06-25 | 2010-09-23 | Crucell Holland B.V. | Binding molecules for the treatment of myeloid cell malignancies |
CN1984931B (zh) * | 2004-06-03 | 2012-11-28 | 诺维莫尼公司 | 抗-cd3抗体及其使用方法 |
SG10201606980VA (en) | 2004-06-03 | 2016-10-28 | Novimmune Sa | Anti-cd3 antibodies and methods of use thereof |
SE527196C2 (sv) | 2004-07-08 | 2006-01-17 | Chemel Ab | SIRE genomflödesdetektor |
JP2008511337A (ja) | 2004-09-02 | 2008-04-17 | ジェネンテック・インコーポレーテッド | ヘテロ多量体分子 |
US20060171929A1 (en) * | 2005-01-31 | 2006-08-03 | The University Of Washington | Regulation of dendritic cell functions by the DCAL-2 receptor |
WO2006105338A2 (en) | 2005-03-31 | 2006-10-05 | Xencor, Inc. | Fc VARIANTS WITH OPTIMIZED PROPERTIES |
ES2592271T3 (es) | 2005-03-31 | 2016-11-29 | Chugai Seiyaku Kabushiki Kaisha | Métodos de producción de polipéptidos mediante la regulación de la asociación de los polipéptidos |
JP2008537941A (ja) * | 2005-03-31 | 2008-10-02 | ゼンコー・インコーポレイテッド | 最適化特性を有するFc変異体 |
GB2429517B (en) | 2005-07-15 | 2010-10-06 | Viridian Concepts Ltd | Solar collector devices |
US20070198410A1 (en) | 2005-10-18 | 2007-08-23 | Labgold Marc R | Credit fraud prevention systems and methods |
WO2007147901A1 (en) | 2006-06-22 | 2007-12-27 | Novo Nordisk A/S | Production of bispecific antibodies |
EP2471816A1 (en) | 2006-08-30 | 2012-07-04 | Genentech, Inc. | Multispecific antibodies |
US8290739B2 (en) | 2006-10-20 | 2012-10-16 | Amfit, Inc. | Method for determining relative mobility of regions of an object |
WO2008119353A1 (en) | 2007-03-29 | 2008-10-09 | Genmab A/S | Bispecific antibodies and methods for production thereof |
AU2008287340A1 (en) | 2007-08-15 | 2009-02-19 | Amunix, Inc. | Compositions and methods for modifying properties of biologically active polypeptides |
EP2211903A4 (en) * | 2007-10-17 | 2011-07-06 | Nuvelo Inc | CLL-1 ANTIBODY |
US8242247B2 (en) | 2007-12-21 | 2012-08-14 | Hoffmann-La Roche Inc. | Bivalent, bispecific antibodies |
US9266967B2 (en) | 2007-12-21 | 2016-02-23 | Hoffmann-La Roche, Inc. | Bivalent, bispecific antibodies |
US20090162359A1 (en) | 2007-12-21 | 2009-06-25 | Christian Klein | Bivalent, bispecific antibodies |
EP2235064B1 (en) | 2008-01-07 | 2015-11-25 | Amgen Inc. | Method for making antibody fc-heterodimeric molecules using electrostatic steering effects |
WO2009098596A2 (en) | 2008-02-05 | 2009-08-13 | Zymeworks Inc. | Methods for determining correlated residues in a protein or other biopolymer using molecular dynamics |
RU2731084C2 (ru) | 2008-06-27 | 2020-08-28 | Мерюс Н.В. | Продуцирующие антитела млекопитающие, не являющиеся человеком |
CN102365296A (zh) | 2009-01-26 | 2012-02-29 | 根马布股份公司 | 用于生成抗体混合物的方法 |
KR20130080871A (ko) | 2009-03-20 | 2013-07-15 | 제넨테크, 인크. | 이중특이적 항-her 항체 |
EP2424567B1 (en) | 2009-04-27 | 2018-11-21 | OncoMed Pharmaceuticals, Inc. | Method for making heteromultimeric molecules |
RU2522002C2 (ru) * | 2009-06-26 | 2014-07-10 | Ридженерон Фармасьютикалз, Инк. | Легковыделяемые биспецифические антитела с природным иммуноглобулиновым форматом |
US9493578B2 (en) * | 2009-09-02 | 2016-11-15 | Xencor, Inc. | Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens |
HUE026229T2 (en) * | 2010-02-08 | 2016-06-28 | Regeneron Pharma | Common light chain mouse |
WO2011143545A1 (en) * | 2010-05-14 | 2011-11-17 | Rinat Neuroscience Corporation | Heterodimeric proteins and methods for producing and purifying them |
EP2603526A1 (en) * | 2010-08-13 | 2013-06-19 | Medimmune Limited | Monomeric polypeptides comprising variant fc regions and methods of use |
EP2606064B1 (en) | 2010-08-16 | 2015-02-25 | NovImmune S.A. | Methods for the generation of multispecific and multivalent antibodies |
BR112013011811A2 (pt) | 2010-11-05 | 2023-02-23 | Zymeworks Inc | Modelo de anticorpo heterodimérico estável com mutações no domínio fc |
EP2688909A2 (en) | 2011-03-25 | 2014-01-29 | Glenmark Pharmaceuticals S.A. | Hetero-dimeric immunoglobulins |
CA2791109C (en) | 2011-09-26 | 2021-02-16 | Merus B.V. | Generation of binding molecules |
KR102382304B1 (ko) | 2012-04-20 | 2022-04-04 | 메뤼스 엔.페. | Ig-유사 분자의 제조방법 및 제조수단 |
CN105051066B (zh) * | 2012-09-27 | 2019-08-06 | 美勒斯公司 | 作为T细胞衔接器的双特异性IgG抗体 |
LT3115376T (lt) | 2015-07-10 | 2018-11-12 | Merus N.V. | Antikūnai, kurie jungiasi su žmogaus cd3 |
-
2013
- 2013-09-27 CN CN201380061615.9A patent/CN105051066B/zh active Active
- 2013-09-27 AU AU2013324527A patent/AU2013324527B9/en active Active
- 2013-09-27 ES ES13777349.5T patent/ES2692951T3/es active Active
- 2013-09-27 NZ NZ630563A patent/NZ630563A/en unknown
- 2013-09-27 RS RS20181217A patent/RS57910B1/sr unknown
- 2013-09-27 PL PL13777349T patent/PL2900694T3/pl unknown
- 2013-09-27 SG SG10201705787VA patent/SG10201705787VA/en unknown
- 2013-09-27 DK DK13777349.5T patent/DK2900694T3/en active
- 2013-09-27 TR TR2018/15768T patent/TR201815768T4/tr unknown
- 2013-09-27 KR KR1020157010993A patent/KR102390177B1/ko active IP Right Grant
- 2013-09-27 LT LTEP13777349.5T patent/LT2900694T/lt unknown
- 2013-09-27 MX MX2015003885A patent/MX2015003885A/es unknown
- 2013-09-27 US US14/040,023 patent/US10358492B2/en active Active
- 2013-09-27 BR BR112015006824A patent/BR112015006824A2/pt not_active Application Discontinuation
- 2013-09-27 CA CA2889681A patent/CA2889681C/en active Active
- 2013-09-27 PT PT13777349T patent/PT2900694T/pt unknown
- 2013-09-27 HU HUE13777349A patent/HUE042040T2/hu unknown
- 2013-09-27 EP EP13777349.5A patent/EP2900694B1/en active Active
- 2013-09-27 JP JP2015534421A patent/JP6471095B2/ja active Active
- 2013-09-27 EP EP18192737.7A patent/EP3470431A1/en active Pending
- 2013-09-27 WO PCT/NL2013/050693 patent/WO2014051433A1/en active Application Filing
- 2013-09-27 SG SG11201502451QA patent/SG11201502451QA/en unknown
- 2013-09-27 EA EA201590640A patent/EA201590640A1/ru unknown
- 2013-09-27 SI SI201331229T patent/SI2900694T1/sl unknown
- 2013-09-27 CN CN201811462337.9A patent/CN110066338B/zh active Active
-
2015
- 2015-03-25 IL IL237945A patent/IL237945B/en unknown
- 2015-04-24 ZA ZA2015/02835A patent/ZA201502835B/en unknown
-
2016
- 2016-01-05 HK HK16100035.9A patent/HK1211966A1/xx unknown
-
2018
- 2018-06-12 AU AU2018204173A patent/AU2018204173B2/en active Active
- 2018-10-19 HR HRP20181717TT patent/HRP20181717T1/hr unknown
- 2018-10-25 CY CY20181101099T patent/CY1120976T1/el unknown
- 2018-11-01 JP JP2018206388A patent/JP2019068803A/ja active Pending
-
2019
- 2019-04-19 US US16/389,356 patent/US20190352393A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20181717T1 (hr) | Bispecifična igg protutijela kao aktivatori t stanice | |
HK1217958A1 (zh) | 四價雙特異性抗體 | |
HK1210620A1 (en) | Multi-specific monoclonal antibodies | |
HK1202563A1 (en) | Sequence symmetric modified igg4 bispecific antibodies igg4 | |
HK1209137A1 (en) | Humanized tau antibody tau | |
EP2922874A4 (en) | BISPECIFIC ANTIBODIES | |
HK1204627A1 (en) | Anti-fcrn antibodies fcrn | |
HK1202565A1 (en) | Sequence symmetric modified igg4 bispecific antibodies igg4 | |
PT2825559T (pt) | Anticorpos biespecíficos prontamente isolados com formato de imunoglobulina nativo | |
HK1204571A1 (en) | Protease-regulated antibodies | |
HK1210192A1 (en) | Anti-siglec-15 antibodies siglec-15 | |
ZA201506568B (en) | Anti-tnf-anti-il-17 bispecific antibodies | |
ZA201407272B (en) | Anti-baff-anti-il-17 bispecific antibodies | |
HK1210186A1 (en) | Anti-h7cr antibodies h7cr | |
HK1202454A1 (en) | Anti-p-selectin antibody formulation -p- |